+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Testis Antigen 1"

Cancer Testis Antigen 1 - Pipeline Review, H2 2019 - Product Thumbnail Image

Cancer Testis Antigen 1 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 76 Pages
  • Global
From
Cancer-Testis Antigen 1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cancer-Testis Antigen 1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 48 Pages
  • Global
From
Cells Expressing Cancer-Testis Antigen 1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing Cancer-Testis Antigen 1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 74 Pages
  • Global
From
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drugs in Development, 2021 - Product Thumbnail Image

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drugs in Development, 2021

  • Report
  • April 2021
  • 50 Pages
  • Global
From
Cells Expressing Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drugs in Development, 2021 - Product Thumbnail Image

Cells Expressing Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drugs in Development, 2021

  • Report
  • April 2021
  • 85 Pages
  • Global
From
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2018 - Product Thumbnail Image

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2018

  • Drug Pipelines
  • August 2018
  • 74 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

The Testis Antigen 1 (TA1) market is a subset of the oncology drug market, focusing on drugs that target TA1-expressing tumors. TA1 is a protein expressed in a variety of cancers, including prostate, ovarian, and bladder cancer. TA1-targeting drugs are designed to block the growth and spread of cancer cells, and can be used in combination with other treatments such as chemotherapy and radiation. TA1-targeting drugs are still in the early stages of development, with only a few drugs currently approved for use in clinical trials. However, the potential of TA1-targeting drugs to improve cancer treatment outcomes has attracted the attention of many pharmaceutical companies. Companies such as Merck, Pfizer, and AstraZeneca are actively researching and developing TA1-targeting drugs, with several drugs in various stages of clinical trials. Additionally, several biotechnology companies, such as ImmunoGen and OncoSec, are also researching and developing TA1-targeting drugs. Show Less Read more